JP2008523100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523100A5 JP2008523100A5 JP2007545699A JP2007545699A JP2008523100A5 JP 2008523100 A5 JP2008523100 A5 JP 2008523100A5 JP 2007545699 A JP2007545699 A JP 2007545699A JP 2007545699 A JP2007545699 A JP 2007545699A JP 2008523100 A5 JP2008523100 A5 JP 2008523100A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound
- compound according
- piperazine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 208000015114 central nervous system disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 3
- 201000010064 diabetes insipidus Diseases 0.000 claims 3
- 201000001881 impotence Diseases 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- -1 2,6-difluorophenyl Chemical group 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- YNEJLDMVMMMAHV-UHFFFAOYSA-N 1-(2-fluoro-3-phenylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC(C=2C=CC=CC=2)=C1F YNEJLDMVMMMAHV-UHFFFAOYSA-N 0.000 claims 1
- KJNPBGFWEFUTPZ-UHFFFAOYSA-N 1-(3-fluoro-5-phenylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C=2C=CC=CC=2)=C1 KJNPBGFWEFUTPZ-UHFFFAOYSA-N 0.000 claims 1
- MKUBXSLBNISCDT-UHFFFAOYSA-N 1-(3-fluoro-5-pyridin-3-ylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C=2C=NC=CC=2)=C1 MKUBXSLBNISCDT-UHFFFAOYSA-N 0.000 claims 1
- VYYXQKHGVNWYPE-UHFFFAOYSA-N 1-(3-fluoro-5-thiophen-3-ylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C2=CSC=C2)=C1 VYYXQKHGVNWYPE-UHFFFAOYSA-N 0.000 claims 1
- XEQNDRIEOQHPEL-UHFFFAOYSA-N 1-(4-fluoro-3-phenylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(F)C(C=2C=CC=CC=2)=C1 XEQNDRIEOQHPEL-UHFFFAOYSA-N 0.000 claims 1
- JVPQIKASKNGHSB-UHFFFAOYSA-N 1-(4-fluoro-3-pyridin-3-ylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(F)C(C=2C=NC=CC=2)=C1 JVPQIKASKNGHSB-UHFFFAOYSA-N 0.000 claims 1
- FYHKQKOXJPJNDZ-UHFFFAOYSA-N 1-[2-fluoro-5-(3-fluorophenyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(C=2C=C(F)C=CC=2)=CC=C1F FYHKQKOXJPJNDZ-UHFFFAOYSA-N 0.000 claims 1
- YATWPSRQRALPNG-UHFFFAOYSA-N 1-[2-fluoro-5-(4-fluorophenyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(C=2C=CC(F)=CC=2)=CC=C1F YATWPSRQRALPNG-UHFFFAOYSA-N 0.000 claims 1
- SOAZRNJAVMYONM-UHFFFAOYSA-N 1-[3-(2,6-difluorophenyl)-5-fluorophenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C=2C(=CC=CC=2F)F)=C1 SOAZRNJAVMYONM-UHFFFAOYSA-N 0.000 claims 1
- MLPMICQNGPHQAU-UHFFFAOYSA-N 1-[3-fluoro-5-(2-fluorophenyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C=2C(=CC=CC=2)F)=C1 MLPMICQNGPHQAU-UHFFFAOYSA-N 0.000 claims 1
- IIWSEIJTHVQWKD-UHFFFAOYSA-N 1-[3-fluoro-5-(3-fluorophenyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C=2C=C(F)C=CC=2)=C1 IIWSEIJTHVQWKD-UHFFFAOYSA-N 0.000 claims 1
- NEJFXIHBUAMRMK-UHFFFAOYSA-N 1-[3-fluoro-5-(4-fluorophenyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C=2C=CC(F)=CC=2)=C1 NEJFXIHBUAMRMK-UHFFFAOYSA-N 0.000 claims 1
- JVUWWLVBYPTVQT-UHFFFAOYSA-N 1-[3-fluoro-5-(furan-3-yl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C2=COC=C2)=C1 JVUWWLVBYPTVQT-UHFFFAOYSA-N 0.000 claims 1
- FVIXIFQFUBZVKB-UHFFFAOYSA-N 2-methyl-1-(3-phenylphenyl)piperazine Chemical compound CC1CNCCN1C1=CC=CC(C=2C=CC=CC=2)=C1 FVIXIFQFUBZVKB-UHFFFAOYSA-N 0.000 claims 1
- COWVYHSMHHWWMH-UHFFFAOYSA-N 2-methyl-1-(5-phenylpyridin-3-yl)piperazine Chemical compound CC1CNCCN1C1=CN=CC(C=2C=CC=CC=2)=C1 COWVYHSMHHWWMH-UHFFFAOYSA-N 0.000 claims 1
- YEOBHMTYJHILQO-UHFFFAOYSA-N 2-methyl-1-(6-phenylpyridin-2-yl)piperazine Chemical compound CC1CNCCN1C1=CC=CC(C=2C=CC=CC=2)=N1 YEOBHMTYJHILQO-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010022773 Intracranial pressure increased Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 125000005392 carboxamide group Chemical class NC(=O)* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004440 haloalkylsulfinyl group Chemical group 0.000 claims 1
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims 1
- 125000004995 haloalkylthio group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 201000000484 premenstrual tension Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63579404P | 2004-12-13 | 2004-12-13 | |
| PCT/US2005/044815 WO2006065706A1 (en) | 2004-12-13 | 2005-12-09 | N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523100A JP2008523100A (ja) | 2008-07-03 |
| JP2008523100A5 true JP2008523100A5 (enExample) | 2009-01-29 |
Family
ID=36120106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545699A Withdrawn JP2008523100A (ja) | 2004-12-13 | 2005-12-09 | ５ｈｔ２ｃ受容体に関連した疾患の治療に有用な５ｈｔ２ｃ受容体のモジュレータとしてのｎ−ビアリール及びｎ−アリールヘテロアリール２−置換ピペラジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080255137A1 (enExample) |
| EP (1) | EP1831188A1 (enExample) |
| JP (1) | JP2008523100A (enExample) |
| CN (1) | CN101084206A (enExample) |
| AU (1) | AU2005316671A1 (enExample) |
| CA (1) | CA2588567A1 (enExample) |
| WO (1) | WO2006065706A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006124865A2 (en) * | 2005-05-19 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Biaryls derivatives useful as modulators of ion channels |
| EP1904491A2 (en) | 2005-05-31 | 2008-04-02 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| PL386429A1 (pl) * | 2008-11-04 | 2010-05-10 | Instytut Farmakologii Polskiej Akademii Nauk | Nowe 4,6-dipodstawione pochodne 2-(4-metylopiperazyn-1-ylo) pirydyny i preparaty farmaceutyczne zawierające te związki oraz ich zastosowanie |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| KR102328323B1 (ko) * | 2017-03-31 | 2021-11-19 | 엑시얼 테라퓨틱스, 인크. | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 |
| WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03010232A (es) * | 2001-05-11 | 2004-03-16 | Biovitrum Ab | Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central. |
| MXPA05013365A (es) * | 2003-06-20 | 2006-04-05 | Arena Pharm Inc | Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c. |
-
2005
- 2005-12-09 JP JP2007545699A patent/JP2008523100A/ja not_active Withdrawn
- 2005-12-09 EP EP05853682A patent/EP1831188A1/en not_active Withdrawn
- 2005-12-09 CN CNA2005800427519A patent/CN101084206A/zh active Pending
- 2005-12-09 AU AU2005316671A patent/AU2005316671A1/en not_active Abandoned
- 2005-12-09 US US11/792,742 patent/US20080255137A1/en not_active Abandoned
- 2005-12-09 WO PCT/US2005/044815 patent/WO2006065706A1/en not_active Ceased
- 2005-12-09 CA CA002588567A patent/CA2588567A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007516941A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| JP2004527467A5 (enExample) | ||
| JP2002523491A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| JP2014526435A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2004519438A5 (enExample) | ||
| JP2017524005A5 (enExample) | ||
| JP2005521671A5 (enExample) | ||
| JP2005518414A5 (enExample) | ||
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| JP2004532823A5 (enExample) | ||
| JP2007502287A5 (enExample) | ||
| JP2004517852A5 (enExample) | ||
| JPWO2000047558A1 (ja) | アミド化合物およびその医薬としての用途 | |
| JP2007508358A5 (enExample) | ||
| JP2002535408A5 (enExample) | ||
| JP2003507367A5 (enExample) | ||
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| CA2663511A1 (en) | Thiazole pyrazolopyrimidines as crf1 receptor antagonists | |
| JP2003507366A5 (enExample) | ||
| JP2011517443A5 (enExample) |